PubMed

Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH).

Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, Murillo AE, Gaire F, Farrell M, Walk E, Penault-Llorca F, Kurosumi M, Dietel M, Wang L, Loftus M, Pettay J, Tubbs RR, Grogan TM.

Diagn Pathol. 2008 Oct 22;3:41.PMID: 18945356 [PubMed - in process]Related articlesFree article

Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.

Dietel M, Ellis IO, Höfler H, Kreipe H, Moch H, Dankof A, Kölble K, Kristiansen G.

Virchows Arch. 2007 Jul;451(1):19-25. Epub 2007 Jun 12.PMID: 17562074 [PubMed - indexed for MEDLINE]Related articles

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.

Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z.

Mod Pathol. 2002 Jun;15(6):657-65.PMID: 12065780 [PubMed - indexed for MEDLINE]Related articlesFree article

The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.

Pedersen M, Rasmussen BB.

Diagn Mol Pathol. 2009 Jun;18(2):96-102.PMID: 19430295 [PubMed - indexed for MEDLINE]Related articles

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.

Dybdal N, Leiberman G, Anderson S, McCune B, Bajamonde A, Cohen RL, Mass RD, Sanders C, Press MF.

Breast Cancer Res Treat. 2005 Sep;93(1):3-11.PMID: 16184453 [PubMed - indexed for MEDLINE]Related articles

Detection of HER2 amplification in breast carcinomas: comparison of Multiplex Ligation-dependent Probe Amplification (MLPA) and Fluorescence In Situ Hybridization (FISH) combined with automated spot counting.

Moerland E, van Hezik RL, van der Aa TC, van Beek MW, van den Brule AJ.

Cell Oncol. 2006;28(4):151-9.PMID: 16988470 [PubMed - indexed for MEDLINE]Related articles

Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: a comparative methodological study using the Ventana BenchMark automated staining system and manual tests.

Bánkfalvi A, Boecker W, Reiner A.

Int J Oncol. 2004 Oct;25(4):929-35.PMID: 15375542 [PubMed - indexed for MEDLINE]Related articles

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists.

J Clin Oncol. 2007 Jan 1;25(1):118-45. Epub 2006 Dec 11.PMID: 17159189 [PubMed - indexed for MEDLINE]Related articles

Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.

Shousha S, Peston D, Amo-Takyi B, Morgan M, Jasani B.

Histopathology. 2009 Jan;54(2):248-53.PMID: 19207950 [PubMed - indexed for MEDLINE]Related articles

Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast.

Downs-Kelly E, Pettay J, Hicks D, Skacel M, Yoder B, Rybicki L, Myles J, Sreenan J, Roche P, Powell R, Hainfeld J, Grogan T, Tubbs R.

Am J Surg Pathol. 2005 Nov;29(11):1505-11.PMID: 16224218 [PubMed - indexed for MEDLINE]Related articles

Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility study.

Tubbs RR, Pettay JD, Swain E, Roche PC, Powell W, Hicks DG, Grogan T.

Appl Immunohistochem Mol Morphol. 2006 Dec;14(4):436-40.PMID: 17122642 [PubMed - indexed for MEDLINE]Related articles

A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.

Powell WC, Hicks DG, Prescott N, Tarr SM, Laniauskas S, Williams T, Short S, Pettay J, Nagle RB, Dabbs DJ, Scott KM, Brown RW, Grogan T, Roche PC, Tubbs RR.

Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):94-102.PMID: 17536315 [PubMed - indexed for MEDLINE]Related articles

Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.

Carbone A, Botti G, Gloghini A, Simone G, Truini M, Curcio MP, Gasparini P, Mangia A, Perin T, Salvi S, Testi A, Verderio P.

J Mol Diagn. 2008 Nov;10(6):527-36. Epub 2008 Oct 2.PMID: 18832456 [PubMed - indexed for MEDLINE]Related articlesFree article

PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.

Ni R, Mulligan AM, Have C, O'Malley FP.

Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):316-24.PMID: 17721278 [PubMed - indexed for MEDLINE]Related articles

Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis.

Turashvili G, Leung S, Turbin D, Montgomery K, Gilks B, West R, Carrier M, Huntsman D, Aparicio S.

BMC Cancer. 2009 May 29;9:165.PMID: 19476653 [PubMed - indexed for MEDLINE]Related articlesFree article

[HER2 status in breast cancer of Chinese women: a study of 1170 cases using fluorescence in-situ hybridization]

Zeng X, Liang ZY, Wu SF, Gao J, Zhou WX, Liu TH.

Zhonghua Bing Li Xue Za Zhi. 2008 Sep;37(9):594-8. Chinese. PMID: 19094582 [PubMed - in process]Related articles

HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization.

Loring P, Cummins R, O'Grady A, Kay EW.

Appl Immunohistochem Mol Morphol. 2005 Jun;13(2):194-200.PMID: 15894935 [PubMed - indexed for MEDLINE]Related articles

Double-target in situ hybridization in brightfield microscopy.

Kerstens HM, Poddighe PJ, Hanselaar AG.

J Histochem Cytochem. 1994 Aug;42(8):1071-7.PMID: 8027526 [PubMed - indexed for MEDLINE]Related articlesFree article

Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.

Dal Lago L, Durbecq V, Desmedt C, Salgado R, Verjat T, Lespagnard L, Ma Y, Veys I, Di Leo A, Sotiriou C, Piccart M, Larsimont D.

Mol Cancer Ther. 2006 Oct;5(10):2572-9.PMID: 17041102 [PubMed - indexed for MEDLINE]Related articlesFree article

HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques.

Ellis CM, Dyson MJ, Stephenson TJ, Maltby EL.

J Clin Pathol. 2005 Jul;58(7):710-4.PMID: 15976337 [PubMed - indexed for MEDLINE]Related articlesFree article